{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T19:03:45Z","timestamp":1743015825607,"version":"3.40.3"},"publisher-location":"Cham","reference-count":38,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783031138287"},{"type":"electronic","value":"9783031138294"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-3-031-13829-4_10","type":"book-chapter","created":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T09:03:13Z","timestamp":1660467793000},"page":"116-125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glioblastoma Subtyping by Immuogenomics"],"prefix":"10.1007","author":[{"given":"Yanran","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandrasekhar","family":"Gopalakrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajasekaran","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caixia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengyong","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,15]]},"reference":[{"key":"10_CR1","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nrneurol.2015.139","volume":"11","author":"M Preusser","year":"2015","unstructured":"Preusser, M., Lim, M., Hafler, D.A., Reardon, D.A., Sampson, J.H.: Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat. Rev. Neurol. 11, 504\u2013514 (2015)","journal-title":"Nat. Rev. Neurol."},{"key":"10_CR2","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","volume":"15","author":"M Lim","year":"2018","unstructured":"Lim, M., Xia, Y., Bettegowda, C., Weller, M.: Current state of immunotherapy for glioblastoma. Nat. Rev. Clin. Oncol. 15, 422\u2013442 (2018)","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma, P., Allison, J.P.: The future of immune checkpoint therapy. Science 348, 56\u201361 (2015)","journal-title":"Science"},{"key":"10_CR4","doi-asserted-by":"crossref","unstructured":"Kelly, P.N.: The cancer immunotherapy revolution. Science 359(6382), 1344\u20131345 (2018)","DOI":"10.1126\/science.359.6382.1344"},{"key":"10_CR5","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A., Wolchok, J.D.: Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018)","journal-title":"Science"},{"key":"10_CR6","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1158\/1078-0432.CCR-18-1538","volume":"25","author":"DB Doroshow","year":"2019","unstructured":"Doroshow, D.B., et al.: Immunotherapy in non\u2013small cell lung cancer: facts and hopes. Clin. Cancer Res. 25, 4592\u20134602 (2019)","journal-title":"Clin. Cancer Res."},{"key":"10_CR7","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh, P.C., et al.: PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568\u2013571 (2014)","journal-title":"Nature"},{"key":"10_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature14432","volume":"523","author":"A Louveau","year":"2015","unstructured":"Louveau, A., et al.: Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337\u2013341 (2015)","journal-title":"Nature"},{"key":"10_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma, P., Allison, J.P.: Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205\u2013214 (2015)","journal-title":"Cell"},{"issue":"2-3","key":"10_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/BF02815350","volume":"21","author":"RL Alterman","year":"1994","unstructured":"Alterman, R.L., Stanley, E.R.: Colony stimulating factor-1 expression in human glioma. Mol. Chem. Neuropathol. 21(2\u20133), 177\u2013188 (1994). https:\/\/doi.org\/10.1007\/BF02815350","journal-title":"Mol. Chem. Neuropathol."},{"key":"10_CR11","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3171\/2009.11.JNS09901","volume":"113","author":"J Miller","year":"2010","unstructured":"Miller, J., et al.: Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma. J. Neurosurg. 113, 280\u2013285 (2010)","journal-title":"J. Neurosurg."},{"key":"10_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.626961","volume":"11","author":"D Mao","year":"2021","unstructured":"Mao, D., Zhou, Z., Song, S., Li, D., Zhang, C.: Identification of stemness characteristics associated with the immune microenvironment and prognosis in gastric cancer. Front. Oncol. 11, 626961 (2021)","journal-title":"Front. Oncol."},{"key":"10_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hnzelmann","year":"2013","unstructured":"Hnzelmann, S., Castelo, R., Guinney, J.: GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinf. 14, 7 (2013)","journal-title":"BMC Bioinf."},{"key":"10_CR14","doi-asserted-by":"crossref","unstructured":"Liu, T., et al.: Ferroptosis, as the most enriched programmed cell death process in glioma, induces immunosuppression and immunotherapy resistance. Neuro-Oncol. 24(7), 1113\u20131125 (2022)","DOI":"10.1093\/neuonc\/noac033"},{"key":"10_CR15","doi-asserted-by":"crossref","unstructured":"Damato, A.R., et al.: A randomized feasibility study evaluating temozolomide circadian medicine in patients with glioma. Neuro-Oncol. Pract. 9(3), 193\u2013200 (2022)","DOI":"10.1093\/nop\/npac003"},{"key":"10_CR16","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/0046-8177(94)90246-1","volume":"25","author":"K Schwechheimer","year":"1994","unstructured":"Schwechheimer, K., L\u00e4ufle, R.M., Schmahl, W., Kn\u00f6dlseder, M., Fischer, H., H\u00f6fler, H.: Expression of neu\/c-erbB-2 in human brain tumors. Hum. Pathol. 25, 772\u2013780 (1994)","journal-title":"Hum. Pathol."},{"key":"10_CR17","first-page":"607","volume":"14","author":"S-L Hwang","year":"1998","unstructured":"Hwang, S.-L., Hong, Y.-R., Chai, C.-Y., Lin, H.-J., Howng, S.-L.: Prognostic evaluation in supratentorial astrocytic tumors using p53, epidermal growth factor receptor, c-erbB-2 immunostaining. Kaohsiung J. Med. Sci. 14, 607\u2013615 (1998)","journal-title":"Kaohsiung J. Med. Sci."},{"key":"10_CR18","first-page":"1489","volume":"25","author":"D Arjona","year":"2004","unstructured":"Arjona, D., et al.: Molecular analysis of the erbB gene family calmodulin-binding and calmodulin-like domains in astrocytic gliomas. Int. J. Oncol. 25, 1489\u20131494 (2004)","journal-title":"Int. J. Oncol."},{"key":"10_CR19","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/bjc.1996.107","volume":"73","author":"H Haapasalo","year":"1996","unstructured":"Haapasalo, H., Hyytinen, E., Sallinen, P., Helin, H., Kallioniemi, O., Isola, J.: C-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization. Br. J. Cancer 73, 620\u2013623 (1996)","journal-title":"Br. J. Cancer"},{"key":"10_CR20","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1002\/ijc.29264","volume":"136","author":"LV Gressot","year":"2015","unstructured":"Gressot, L.V., et al.: Signal transducer and activator of transcription 5b drives malignant progression in a PDGFB-dependent proneural glioma model by suppressing apoptosis. Int. J. Cancer 136, 2047\u20132054 (2015)","journal-title":"Int. J. Cancer"},{"key":"10_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/neuonc\/nov172","volume":"18","author":"EK Nduom","year":"2015","unstructured":"Nduom, E.K., et al.: PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. 18, 195\u2013205 (2015)","journal-title":"Neuro Oncol."},{"key":"10_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-019-1086-5","volume":"20","author":"F Liu","year":"2020","unstructured":"Liu, F., Huang, J., Liu, X., Cheng, Q., Luo, C., Liu, Z.: CTLA-4 correlates with immune and clinical characteristics of glioma. Cancer Cell Int. 20, 1\u201310 (2020)","journal-title":"Cancer Cell Int."},{"key":"10_CR23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1158\/2326-6066.CIR-15-0151","volume":"4","author":"DA Reardon","year":"2016","unstructured":"Reardon, D.A., et al.: Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol. Res. 4, 124\u2013135 (2016)","journal-title":"Cancer Immunol. Res."},{"key":"10_CR24","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1158\/1078-0432.CCR-06-2070","volume":"13","author":"PE Fecci","year":"2007","unstructured":"Fecci, P.E., et al.: Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ t cell compartment without affecting regulatory t-cell function. Clin. Cancer Res. 13, 2158\u20132167 (2007)","journal-title":"Clin. Cancer Res."},{"key":"10_CR25","doi-asserted-by":"crossref","unstructured":"Xu, J, Liu, F., Li, Y., Shen, L.: A 1p\/19q codeletion-associated immune signature for predicting lower grade glioma prognosis. Cell. Mol. Neurobiol. 42(3), 709\u2013722 (2022)","DOI":"10.1007\/s10571-020-00959-3"},{"key":"10_CR26","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10549-007-9594-8","volume":"108","author":"F Andre","year":"2008","unstructured":"Andre, F., et al.: HER2 expression and efficacy of preoperative paclitaxel\/FAC chemotherapy in breast cancer. Breast Cancer Res. Treat. 108, 183\u2013190 (2008)","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10_CR27","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s00066-014-0743-9","volume":"191","author":"H Wichmann","year":"2014","unstructured":"Wichmann, H., et al.: Targeting of EGFR and HER2 with therapeutic antibodies and siRNA. Strahlenther. Onkol. 191(2), 180\u2013191 (2014). https:\/\/doi.org\/10.1007\/s00066-014-0743-9","journal-title":"Strahlenther. Onkol."},{"key":"10_CR28","doi-asserted-by":"crossref","unstructured":"Liu, Y., et al.: Biomimetic manganese-eumelanin nanocomposites for combined hyperthermia-immunotherapy against prostate cancer. J. Nanobiotechnol. 20, 48\u2013(2022)","DOI":"10.1186\/s12951-022-01248-5"},{"key":"10_CR29","doi-asserted-by":"crossref","unstructured":"Xu, G., Luo, Y., Wang, H., Wang, Y., Liu, B., Wei, J.: Therapeutic bispecific antibodies against intracellular tumor antigens. Cancer Lett. 538, 215699 (2022)","DOI":"10.1016\/j.canlet.2022.215699"},{"key":"10_CR30","doi-asserted-by":"crossref","unstructured":"Cui, M., Huang, J, Zhang, S., Liu, Q., Qiu, X.: Immunoglobulin expression in cancer cells and its critical roles in tumorigenesis. Front. Immunol. 12, 613530 (2021)","DOI":"10.3389\/fimmu.2021.613530"},{"key":"10_CR31","doi-asserted-by":"crossref","unstructured":"Wasserman, A.J., Gardner, C.R., Laskin, D.L.: Phagocytosis of tumor cells by activated liver macrophages (1987)","DOI":"10.1017\/S0424820100127918"},{"key":"10_CR32","doi-asserted-by":"crossref","unstructured":"Wherry, E.J., Blattman, J.N., Murali-Krishna, K., Van der Most, R., Ahmed, R.: Viral persistence alters CD8 t-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77, 4911\u20134927 (2003)","DOI":"10.1128\/JVI.77.8.4911-4927.2003"},{"key":"10_CR33","doi-asserted-by":"crossref","unstructured":"Woroniecka, K., Chongsathidkiet, P., Rhodin, K.E., Kemeny, H.R., Fecci, P.E.: T cell exhaustion signatures vary with tumor type and are severe in glioblastoma. Clin. Cancer Res. 24, 1846 (2018)","DOI":"10.1158\/1078-0432.CCR-17-1846"},{"key":"10_CR34","doi-asserted-by":"crossref","unstructured":"Wainwright, D.A., Balyasnikova, I.V., Chang, A.L., Ahmed, A.U., Lesniak, M.S.: IDO expression in brain tumors increases the recruitment of regulatory t cells and negatively impacts survival. Clin. Cancer Res. 18 (2012)","DOI":"10.1158\/1078-0432.CCR-12-2130"},{"key":"10_CR35","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.1158\/1078-0432.CCR-14-0514","volume":"20","author":"DA Wainwright","year":"2014","unstructured":"Wainwright, D.A., et al.: Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin. Cancer Res. 20, 5290\u20135301 (2014)","journal-title":"Clin. Cancer Res."},{"key":"10_CR36","doi-asserted-by":"crossref","unstructured":"Schneider, J.R., Kevin, K., Boockvar, J.A.: Use of HER2-specific chimeric antigen receptor-modified virus-specific t cells as a potential therapeutic for progressive HER2-positive glioblastoma. Neurosurgery N42","DOI":"10.1093\/neuros\/nyx449"},{"key":"10_CR37","doi-asserted-by":"crossref","unstructured":"Hung, A.L., et al.: TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. Oncoimmunology e1466769 (2018)","DOI":"10.1080\/2162402X.2018.1466769"},{"key":"10_CR38","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1002\/eji.201545480","volume":"45","author":"F Wang","year":"2015","unstructured":"Wang, F., et al.: TIGIT expression levels on human NK cells correlate with functional heterogeneity among healthy individuals. Eur. J. Immunol. 45, 2886\u20132897 (2015)","journal-title":"Eur. J. Immunol."}],"container-title":["Lecture Notes in Computer Science","Intelligent Computing Theories and Application"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-13829-4_10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T20:04:53Z","timestamp":1710360293000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-13829-4_10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9783031138287","9783031138294"],"references-count":38,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-13829-4_10","relation":{},"ISSN":["0302-9743","1611-3349"],"issn-type":[{"type":"print","value":"0302-9743"},{"type":"electronic","value":"1611-3349"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"15 August 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"ICIC","order":1,"name":"conference_acronym","label":"Conference Acronym","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"International Conference on Intelligent Computing","order":2,"name":"conference_name","label":"Conference Name","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"Xi'an","order":3,"name":"conference_city","label":"Conference City","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"China","order":4,"name":"conference_country","label":"Conference Country","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"2022","order":5,"name":"conference_year","label":"Conference Year","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"7 August 2022","order":7,"name":"conference_start_date","label":"Conference Start Date","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"11 August 2022","order":8,"name":"conference_end_date","label":"Conference End Date","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"18","order":9,"name":"conference_number","label":"Conference Number","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"icic2022","order":10,"name":"conference_id","label":"Conference ID","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"http:\/\/www.ic-icc.cn\/2022\/index.htm","order":11,"name":"conference_url","label":"Conference URL","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"Open","order":1,"name":"type","label":"Type","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"IC-ICC-CN","order":2,"name":"conference_management_system","label":"Conference Management System","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"449","order":3,"name":"number_of_submissions_sent_for_review","label":"Number of Submissions Sent for Review","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"209","order":4,"name":"number_of_full_papers_accepted","label":"Number of Full Papers Accepted","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"0","order":5,"name":"number_of_short_papers_accepted","label":"Number of Short Papers Accepted","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"47% - The value is computed by the equation \"Number of Full Papers Accepted \/ Number of Submissions Sent for Review * 100\" and then rounded to a whole number.","order":6,"name":"acceptance_rate_of_full_papers","label":"Acceptance Rate of Full Papers","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"3","order":7,"name":"average_number_of_reviews_per_paper","label":"Average Number of Reviews per Paper","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"2.5","order":8,"name":"average_number_of_papers_per_reviewer","label":"Average Number of Papers per Reviewer","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"No","order":9,"name":"external_reviewers_involved","label":"External Reviewers Involved","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}}]}}